Pipeline

February 21, 2020

Company	Drug/Device	Medical Condition	Status
Atreca	ATRC-101	Select solid tumor cancers	phase 1 first patient dosed
AXIM Biotechnologies	cannabinoid-based chewing gum with dronabinol	chemotherapy-related symptoms	phase 1 completed
Applied Genetic Technologies	AGTC-501	X-linked retinitis pigmentosa	phase 1/2 enrollment completed
Molecular Templates	TAK-169	relapsed/refractory multiple myeloma	phase 1 dosing initiated
Cyclo Therapeutics	Trappsol Cyclo	Niemann-Pick disease Type C	phase 1/2 patient enrollment completed
Harbour BioMed	HBM9161	autoimmune diseases	phase 1 completed
ImmunogenX	Latiglutenase (IMGX003)	celiac disease	phase 2b enrollment started
Aravive	AVB-500	platinum-resistant recurrent ovarian cancer	phase 1b enrollment started for higher dosage
BioXcel Therapeutics	BXCL501	agitation in schizophrenia	phase 2 trial initiated
RIBOMIC	RBM-007	exudative age-related macular degeneration	phase 2 first patient injected
DelMar Pharmaceuticals	VAL-083	newly diagnosed, MGMT-unmethylated glioblastoma multiforme	phase 2 final patient enrolled and dosed
Palatin Technologies	topical PL9643	dry eye disease	phase 2 initiated, first patient enrolled
Compugen	COM701, in combination with nivolumab and BMS-986207	advanced solid tumors	phase 1/2 plans for initiation
Dyve Biosciences	DYV-700	acute gout	phase 2 initiated, first patient enrolled
VBL Therapeutics	VB-111 in combination with nivolumab	metastatic colorectal cancer	phase 2 initiated
SCYNEXIS	ibrexafungerp	vulvovaginal candidiasis	phase 3 enrollment completed
Isofol Medical	arfolitixorin	metastatic colorectal cancer	phase 3 first patient in Japan dosed
Alnylam Pharmaceuticals	vutrisiran	ATTR amyloidosis	phase 3 enrollment completed
Axsome Therapeutics	AXS-007	migraines	phase 3 enrollment completed
Epizyme	TAZVERIK (tazemetostat)	follicular lymphoma	priority review granted by the FDA
Seattle Genetics Astellas Pharma	PADCEV (enfortumab vedotin-ejfv)	advanced bladder cancer	Breakthrough Therapy designation awarded by the FDA
Cardiovalve	Transcatheter Tricuspid Valve Replacement System	tricuspid regurgitation	Breakthrough Therapy designation awarded by the FDA
Horizon Therapeutics	PROCYSBI (cysteamine bitartrate)	nephropathic cystinosis	new dosage form approved by the FDA
Agile Therapeutics	Twirla (levonorgestrel and ethinyl estradiol) transdermal system	female hormone deficiency	approved by the FDA
Baudax Bio	ANJESO (meloxicam injection)	management of moderate to severe pain	approved by the FDA
Bristol-Myers Squibb	Opdivo (nivolumab)	unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy	approved by the Japan Ministry of Health, Labor and Welfare